scPharmaceuticals (NASDAQ:SCPH) Rating Increased to Hold at Wall Street Zen

Key Points

• scPharmaceuticals (NASDAQ:SCPH) has been upgraded to a "hold" rating by Wall Street Zen, while other analysts like HC Wainwright and Craig Hallum also adjusted their ratings to "hold" with price targets of $5.35 and $6.00, respectively.
• The company reported a negative EPS of ($0.34) for the last quarter, falling short of analyst estimates, but generated a revenue of $16.04 million, exceeding the consensus estimate.
• Institutional investors hold a significant interest in scPharmaceuticals, with 89.52% of the stock owned by such investors after recent increases in holdings by firms like Captrust Financial Advisors and Balanced Rock Investment Advisors.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) was upgraded by Wall Street Zen to a "hold" rating in a note issued to investors on Saturday.

A number of other analysts have also recently weighed in on the stock. HC Wainwright cut shares of scPharmaceuticals from a "strong-buy" rating to a "hold" rating and set a $5.35 price objective on the stock. in a report on Friday, August 29th. Craig Hallum downgraded shares of scPharmaceuticals from a "buy" rating to a "hold" rating and set a $6.00 target price on the stock. in a report on Monday, August 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of scPharmaceuticals in a report on Wednesday. Finally, Maxim Group downgraded shares of scPharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, August 25th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Reduce" and a consensus price target of $7.78.

scPharmaceuticals Stock Performance

Shares of SCPH stock opened at $5.67 on Friday. The company has a market capitalization of $302.20 million, a PE ratio of -3.13 and a beta of 0.31. The firm has a fifty day simple moving average of $5.38 and a 200-day simple moving average of $4.14. scPharmaceuticals has a twelve month low of $1.94 and a twelve month high of $6.28.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.04). scPharmaceuticals had a negative net margin of 183.55% and a negative return on equity of 1,647.86%. The company had revenue of $16.04 million for the quarter, compared to the consensus estimate of $15.41 million. Equities research analysts predict that scPharmaceuticals will post -1.53 EPS for the current year.

Institutional Trading of scPharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Captrust Financial Advisors boosted its holdings in scPharmaceuticals by 9.0% in the 2nd quarter. Captrust Financial Advisors now owns 43,746 shares of the company's stock valued at $167,000 after purchasing an additional 3,621 shares during the period. Balanced Rock Investment Advisors LLC raised its stake in shares of scPharmaceuticals by 27.8% in the 2nd quarter. Balanced Rock Investment Advisors LLC now owns 90,968 shares of the company's stock valued at $347,000 after buying an additional 19,768 shares in the last quarter. Pale Fire Capital SE acquired a new position in shares of scPharmaceuticals in the 2nd quarter valued at $218,000. Walleye Capital LLC acquired a new position in shares of scPharmaceuticals in the 2nd quarter valued at $43,000. Finally, Lido Advisors LLC raised its stake in shares of scPharmaceuticals by 14.6% in the 2nd quarter. Lido Advisors LLC now owns 27,500 shares of the company's stock valued at $105,000 after buying an additional 3,500 shares in the last quarter. 89.52% of the stock is owned by institutional investors.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.